↓ Skip to main content

Dove Medical Press

Article Metrics

Ginsenoside Rg1 nanoparticle penetrating the blood–brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction

Overview of attention for article published in International Journal of Nanomedicine, September 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
2 tweeters
patent
1 patent

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
23 Mendeley
Title
Ginsenoside Rg1 nanoparticle penetrating the blood–brain barrier to improve the cerebral function of diabetic rats complicated with cerebral infarction
Published in
International Journal of Nanomedicine, September 2017
DOI 10.2147/ijn.s139602
Pubmed ID
Authors

Junyi Shen, Zhiming Zhao, Wei Shang, Chunli Liu, Beibei Zhang, Lingjie Zhao, Hui Cai

Abstract

Diabetic cerebral infarction is with poorer prognosis and high rates of mortality. Ginsenoside Rg1 (Rg1) has a wide variety of therapeutic values for central nervous system (CNS) diseases for the neuron protective effects. However, the blood-brain barrier (BBB) restricts Rg1 in reaching the CNS. In this study, we investigated the therapeutic effects of Rg1 nanoparticle (PHRO, fabricated with γ-PGA, L-PAE (H), Rg1, and OX26 antibody), targeting transferrin receptor, on the diabetes rats complicated with diabetic cerebral infarction in vitro and in vivo. Dynamic light scattering analysis shows the average particle size of PHRO was 79±18 nm and the polydispersity index =0.18. The transmission electron microscope images showed that all NPs were spherical in shape with diameters of 89±23 nm. PHRO released Rg1 with sustained release manner and could promote the migration of cerebrovascular endothelial cells and tube formation and even penetrated the BBB in vitro. PHRO could penetrate the BBB with high concentration in brain tissue to reduce the cerebral infarction volume and promote neuronal recovery in vivo. PHRO was promising to be a clinical treatment of diabetes mellitus with cerebral infarction.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 26%
Student > Ph. D. Student 3 13%
Student > Master 3 13%
Researcher 2 9%
Student > Postgraduate 2 9%
Other 5 22%
Unknown 2 9%
Readers by discipline Count As %
Medicine and Dentistry 5 22%
Biochemistry, Genetics and Molecular Biology 4 17%
Neuroscience 4 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 9%
Agricultural and Biological Sciences 2 9%
Other 2 9%
Unknown 4 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2019.
All research outputs
#5,109,901
of 17,365,229 outputs
Outputs from International Journal of Nanomedicine
#505
of 3,178 outputs
Outputs of similar age
#92,222
of 279,742 outputs
Outputs of similar age from International Journal of Nanomedicine
#9
of 60 outputs
Altmetric has tracked 17,365,229 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,178 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,742 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.